### PATENT COOPERATION TREATY

PA'	TENT COOPER	ATION TREAT	Y TRAN				
INTERNATIONAL SEARCHING AUTHOR	ITY		· · · · · · · · · · · · · · · · · · ·				
То:			PCT PCT				
			ITTEN OPINION OF THE DNAL SEARCHING AUTHORITY				
		(PCT Rule 43bis.1)					
		Date of mailing (day/month/year)	See Form PCT/ISA/210 (sheet 2)				
Applicant's or agent's file reference  SM 5273-03WO	<del>-</del>	FOR FURTHER ACTION  See paragraph 2 below					
International application No.	International filing date (	day/month/year)	Priority date (day/month/year)				
PCT/EP2005/003329	30.03.2005		02.04.2004				
International Patent Classification (IPC) or both national classification and IPC  A61 K7/48, A61 K7/02							
Applicant SCHWAN-STABILO COSMETICS GMBH & CO. KG.							
This opinion contains indications relat	ing to the following items	:					
Box No. I Basis of the							
Box No. II Priority							
Box No. III Non-establis	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unit	Box No. IV Lack of unity of invention						
Box No. V Reasoned state applicability	Box No. V  Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain docu	iments cited						
Box No. VII Certain defe	cts in the international app	plication					
Box No. VIII Certain obse	Box No. VIII Certain observations on the international application						
2. FURTHER ACTION							
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.							
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.							
For further options, see Form PCT/ISA/220.							
3. For further details, see notes to Form	PCT/ISA/220.						
Name and mailing address of the ISA/EP		Authorized officer					
Facsimile No.		Telephone No.					

International application No.
PCT/EP2005/003329

Box	k No. I	Basis of this opinion
1.	With filed	regard to the language, this opinion has been established on the basis of the international application in the language in which it was unless otherwise indicated under this item.
		This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under
	-	Rule 12.3 and 23.1(b)).
2.		regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ation, this opinion has been established on the basis of:
	a.	type of material
		a sequence listing
		table(s) related to the sequence listing
	b.	format of material
		in written format
		in computer readable form
	c.	time of filing/furnishing
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Add	itional comments:
		·
		·
1		

International application No.
PCT/EP2005/003329

Box No. V Reasoned statement under R citations and explanations su			tule 43bls.1(a)(i) with regard to novelty, inventive step or industrial applicability; apporting such statement		
1.	Statement				
	Novelty (N	<b>v</b> )	Claims	21, 30-32	YES
			Claims	1-20, 22-29	NO
	Inventive :	step (IS)	Claims		YES
			Claims	1-32	NO
	Industrial	applicability (IA)	Claims	1-32	YES
			Claims		NO

#### 2. Citations and explanations:

Reference is made to the following documents:

D1: US-B1-6 491 931

D2: WO 03/094868 A

D3: EP-A-1 213 010

D4: EP-A-1 541 126

D5: EP-A-O 987 016

D6: EP-A-0 832 645

#### Novelty

Claim 1 discloses that the preparation contains at least two polymers. A person skilled in the art would interpret this expression to mean that the preparations contain two different polymers in the form of a blend. The conditions stated in claim 8, according to which the two polymers can be present in the form of a copolymer, would not be interpreted in this manner by a person skilled in the art. The subject matter of claims 1-7, 9-32 is therefore not clear (PCT Article 6). The disclosure in claim 8 should be added to claim 1.

D1 (example 1/film-forming copolymer: polyester-polyurethane) discloses an oil-in-water emulsion that is prejudicial to the novelty of claims 1-2, 4, 8, 10, 13,

International application No.
PCT/EP2005/003329

Box No. V

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

15-18, 22-26, 28 (PCT Article 33(2)).

D2 (examples 1, 2, 4, 5, 7) discloses make-ups that are prejudicial to the novelty of claims 1-13, 15-16, 18-20, 22-26, 28 (PCT Article 33(2)).

D3 (examples 2 (1-2, 4-6); 3(3)) discloses make-ups that are prejudicial to the novelty of claims 1-13, 15-16, 18, 20, 22-26, 28.

D4 was published on 15 June 2005, i.e. after the filing date of the present application. When the present application enters the regional European phase before the EPO, D4 may become prior art according to EPC Article 54(3). Examples 56-60 in D4 are prejudicial to the novelty of the present invention.

The claimed formulations are the result of a multiple selection from the disclosures in D5. The formulations of the examples in D5 do not contain pigment. The subject matter of claims 1-32 is therefore novel.

The formulations of examples 4, 6, 7, 12, 13, 14, 15, 19 in D6 are prejudicial to the novelty of claims 1-11, 13, 15-16, 18-20, 22-29.

#### Inventive step

The present application does not meet the requirements of PCT Article 33(1) because the subject matter of claims 1-32 is not based on an inventive step within the meaning of PCT Article 33(3).

International application No.
PCT/EP2005/003329

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

It is clear from document D5 that film-forming polymers are used as an anti-wrinkle coating (paragraphs 1, 4-6, 15-37, 67). According to documents D1, D2, D6, the preparations according to the invention are like a second skin, they do not migrate, do not transfer, do not stick, produce an elastic film that adheres at the point of application, are particularly stable ... (D2; page 5, line 8 to page 6, line 17; D6: page 2, lines 40-47; D1: column 1, lines 54-63).

Hence the formulations and their properties are already known or foreseeable, and the solution proposed in claims 1-32 of the present application cannot be considered inventive (PCT Article 33(3)).